OTC Statins: Opportunity or Threat?

Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatatin survival study (4S). Lancet 1994;344:1383–9.

Downs JR Clearfield M Weis S Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 1988;279:1615–22.

Shepherd J Cobbe SM Ford I Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 1995;333:1301–7.

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57.

Sacks FM Pfeffer MA Moye LA The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–9.

Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7–22.

Waters D . Statins and safety: applying the results of randomized trials to clinical practice. Am J Cardiol 2003;92:692–5.

Pasternak RC Smith SC Jr Bairey-Merz CN Grundy SM Cleeman JI Lenfant C . ACC/AHA/HNLBI Clinical advisory on the use and safety of statins. Circulation 2002;106:1024–8.

Wooltorton E . Rosuvastatin (Crestor) and rhabdomyolysis. CMAJ 2004;171(2):129.

Stafford E . Patient commentary: paying to choose. BMJ 2004;328:402.

OTC statins: a bad decision for public health. Lancet 2004;363:1659.

Genest J Frohlich J Fodor G McPherson R . Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: 2003 update. CMAJ 2003;168(9):921–4.

Tsuyuki RT Johnson JA Teo KK Simpson SH Ackman ML Biggs RS A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002;162:1149–55.

Tsuyuki RT Olson KL Dubyk AM Schinel TJ Johnson JA . Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Am J Med 2004;116:130–3.

Merenich JA Lousberg TR Brennan SH Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed care environment (the Rocky Mountain Kaiser Permanente experience). Am J Cardiol 2000;85(3A):36A–42A.

Taylor JR Lopez LM . Cholesterol: point-of-care testing. Ann Pharmacother 2004;38:1252–7.

de Denus S Spinler SA Miller K Peterson AM . Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004;24(5):584–91.

Canadian Pharmacists Association. Pharmacists and Primary Health Care. Ottawa: Canadian Pharmacists Association; 2004.

Simpson SH Johnson JA Biggs C Biggs RA Kuntz A Semchuk W Practice-based research: lessons from community pharmacist participants. Pharmacotherapy 2001;21(6):731–9.